Azevan Pharmaceuticals, Inc. announced results from the phase 2 exploratory clinical study of the Company’s lead compound, SRX246, in adults with Intermittent Explosive Disorder. The primary endpoint and exploratory goals of the trial were achieved. Read more: http://prn.to/2cbhJ6y
Client & Alumni News
Azevan Reports Positive Clinical Study Results for Intermittent Explosive Disorder
The Ben Franklin Technology Partners is an initiative of the Pennsylvania Department of Community and Economic Development and is funded by the Ben Franklin Technology Development Authority.